Advertise on podcast: Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we unpack mixed connective tissue disease—recognize the overlap syndrome hiding between lupus, scleroderma, and myositis, and aggressively monitor the pulmonary complications that drive morbidity and mortality. MCTD is defined by high-titer anti-U1 RNP antibodies plus overlapping connective tissue disease features. The hallmark clues: • Raynaud phenomenon • Swollen hands • Sclerodactyly • Inflammatory arthritis • Myositis • GERD and esophageal dysmotility Raynaud’s is often the earliest manifestation, and scleroderma-type findings help distinguish MCTD from lupus in anti-RNP–positive patients. The major threat is pulmonary disease: • Interstitial lung disease (ILD) • Pulmonary arterial hypertension (PAH) PAH remains the leading cause of death, making routine pulmonary surveillance essential: • Pulmonary function tests with DLCO • High-resolution CT when indicated • Echocardiography for PAH screening Treatment depends on organ involvement: • Steroids for inflammatory flares • Mycophenolate, methotrexate, or cyclophosphamide for ILD and systemic disease • Rituximab for refractory cases For MCTD-associated PAH: • Endothelin receptor antagonists • PDE-5 inhibitors • Prostacyclin pathway therapy • Immunosuppression may help more than in systemic sclerosis–associated PAH. Key pearl: many patients achieve remission or stable disease, but up to one-quarter eventually evolve into a more defined connective tissue disease—most commonly systemic sclerosis or lupus. We close with the system moves: don’t dismiss Raynaud’s plus swollen hands as “nonspecific,” screen aggressively for ILD and PAH, trend pulmonary function over time, and recognize that lung complications—not arthritis—determine long-term outcomes in MCTD. The antibody may define the diagnosis, but the lungs define the prognosis.

In this episode of Hospital Medicine Unplugged, we break down myelodysplastic syndromes—recognize the unexplained cytopenias, understand the modern molecular classification, and risk-stratify patients before progression to AML. The WHO 2022 classification shifted MDS from a purely morphologic disease to a genetically informed diagnosis. New entities include MDS with SF3B1 mutation, isolated del(5q), and biallelic TP53-mutated MDS, one of the highest-risk subtypes. Blast categories are now simplified into low blasts, increased blasts-1 (5–9%), and increased blasts-2 (10–19%). Diagnosis requires: • Persistent cytopenias • Dysplasia in >10% of a marrow lineage or defining cytogenetic abnormalities • Exclusion of alternative causes Bone marrow biopsy remains essential, and unexplained cytopenias with clonal mutations that don’t meet MDS criteria are now classified as CCUS. Risk stratification centers on the IPSS-R, incorporating: • Cytogenetics • Blast percentage • Hemoglobin • Platelets • Neutrophil count Lower-risk disease focuses on symptom control and transfusion reduction. Higher-risk disease focuses on delaying AML transformation and improving survival. For anemia in lower-risk MDS: • ESAs remain common first-line therapy • Luspatercept is especially effective in SF3B1-mutated or ring sideroblast disease and outperformed epoetin alfa in recent trials. For higher-risk disease: • Azacitidine is standard frontline therapy and improves overall survival • Decitabine is an alternative • Oral decitabine-cedazuridine allows outpatient treatment Key pearl: responses to hypomethylating agents are delayed—patients often need at least 4–6 cycles before declaring failure. The only curative therapy is allogeneic stem cell transplantation: • Consider for higher-risk disease and select lower-risk patients with severe cytopenias or poor-risk mutations • Reduced-intensity conditioning expanded transplant eligibility into older adults • TP53-mutated disease remains particularly challenging, even after transplant We close with the system moves: investigate unexplained macrocytic anemia and cytopenias early, integrate molecular testing into diagnosis and prognosis, avoid prematurely stopping hypomethylating therapy, and refer transplant-eligible patients before progression to AML. Not every pancytopenia is “just aging marrow”—sometimes it’s a clonal stem-cell disorder announcing itself before leukemia arrives.

In this episode of Hospital Medicine Unplugged, we unpack cardiac amyloidosis—recognize the red flags hiding inside “routine HFpEF,” diagnose ATTR noninvasively, and start disease-modifying therapy before restrictive physiology becomes irreversible. ATTR cardiac amyloidosis is far more common than previously recognized, especially in older adults with HFpEF and increased LV wall thickness. Key clues include voltage-mass discordance—thick ventricles on echo with surprisingly low ECG voltage—and extracardiac findings like carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, or biceps tendon rupture that may precede diagnosis by years. Echo pearls: • Increased wall thickness with preserved EF • Restrictive filling pattern • Biatrial enlargement • Classic “apical sparing” strain pattern The modern diagnostic breakthrough is nuclear imaging: • Grade 2–3 uptake on technetium-PYP scan + negative monoclonal protein testing = essentially diagnostic for ATTR-CM without biopsy. Never skip monoclonal protein screening: • Serum free light chains • Serum immunofixation • Urine immunofixation This distinction matters because AL amyloidosis is a hematologic emergency requiring plasma-cell–directed therapy. Treatment changed dramatically with tafamidis: • Reduces mortality • Lowers cardiovascular hospitalizations • Works best when started early Acoramidis joined the field in 2024 as another TTR stabilizer with similar benefits. Heart failure management is different here: • Loop diuretics are the backbone • ACE inhibitors, ARBs, and beta-blockers are often poorly tolerated • Avoid digoxin and non-dihydropyridine calcium channel blockers Key pearl: anticoagulate atrial fibrillation regardless of CHA₂DS₂-VASc score due to extreme thromboembolic risk. We close with the system moves: when HFpEF doesn’t quite fit—especially with unexplained LVH, neuropathy, orthopedic history, or voltage-mass discordance—think amyloid early, order monoclonal protein studies plus PYP scanning, and start disease-modifying therapy before fibrosis and restrictive failure dominate the trajectory. Not all HFpEF is hypertensive heart disease—sometimes the diagnosis is hiding in the carpal tunnel scar.

In this episode of Hospital Medicine Unplugged, we tackle sarcoidosis—recognize the classic presentations, screen aggressively for silent organ involvement, and treat the patients at highest risk for irreversible damage or sudden death. Diagnosis requires three things: compatible clinical presentation, non-caseating granulomas, and exclusion of alternative granulomatous disease like TB, fungal infection, or malignancy. Some syndromes are classic enough to skip biopsy, including Löfgren syndrome (bilateral hilar adenopathy, erythema nodosum, arthritis, fever) and lupus pernio. Most hospitalized patients, though, need tissue confirmation—typically via EBUS-guided transbronchial needle aspiration for intrathoracic lymphadenopathy. Once diagnosed, the mission shifts to multisystem screening: • Pulmonary: chest imaging + PFTs with DLCO • Cardiac: ECG for all patients; cardiac MRI or FDG PET for symptoms, arrhythmias, or conduction disease • Ophthalmologic: slit-lamp examination • Labs: CBC, creatinine, calcium, alkaline phosphatase, vitamin D metabolites when indicated Cardiac sarcoidosis is a major killer and can present with AV block, ventricular arrhythmias, syncope, or unexplained cardiomyopathy. Neurosarcoidosis can cause cranial neuropathies, meningitis, seizures, or spinal cord disease—both require aggressive recognition and treatment. Not all sarcoidosis needs therapy. Treat when there’s risk of organ damage, death, or severe symptoms: • Cardiac sarcoidosis • Neurosarcoidosis • Progressive pulmonary disease • Ocular disease • Symptomatic hypercalcemia Treatment backbone: • Prednisone 20–40 mg/day for most disease • Higher-dose steroids for cardiac/neuro involvement • IV methylprednisolone for life-threatening presentations Steroid-sparing therapy matters early: • Methotrexate is the preferred second-line agent • Azathioprine, mycophenolate, and leflunomide are alternatives • Infliximab or other biologics for refractory disease Cardiac sarcoidosis often needs more than immunosuppression: • ICDs for ventricular arrhythmia risk • Pacemakers for conduction disease • Catheter ablation for refractory VT Key inpatient pearls: • Monitor calcium and steroid toxicity • Use telemetry if cardiac involvement suspected • Watch for progressive hypoxemia or arrhythmias • Involve pulmonology, cardiology, ophthalmology, and neurology early We close with the system moves: build a standardized sarcoidosis screening pathway, default to ECG + pulmonary testing + ophthalmology evaluation at diagnosis, escalate rapidly to cardiac imaging when red flags appear, and initiate steroid-sparing therapy early for chronic disease. Granulomas are only the start—screen every organ, respect cardiac sarcoidosis, and treat before inflammation becomes permanent fibrosis.

In this episode of Hospital Medicine Unplugged, we unpack autoimmune encephalitis—recognize the red flags early, treat aggressively before antibody results return, and support the long recovery arc that often extends years beyond discharge. We open with the bedside reality: autoimmune encephalitis is frequently missed because it masquerades as psychiatry, infection, toxic-metabolic disease, or unexplained delirium. The key clue is rapid progression over days to weeks with combinations of psychiatric symptoms, memory loss, seizures, dyskinesias, autonomic instability, speech dysfunction, or decreased consciousness. Diagnosis starts clinically—not with waiting for antibodies. The Graus 2016 framework emphasizes a tiered approach using history, exam, MRI, EEG, CSF, and syndrome recognition. For anti-NMDA receptor encephalitis, probable diagnosis requires rapid onset (1,500 patients showed therapeutic apheresis alone or combination regimens (steroids + IVIG or all three modalities) had the best odds of favorable recovery. Failure to initiate immunotherapy within 30 days was associated with markedly worse outcomes. If first-line treatment stalls: • Rituximab becomes the preferred second-line agent • Cyclophosphamide remains an option in refractory disease • Escalation should happen early in severe or persistent cases rather than waiting months Rituximab deserves special attention—it not only improves refractory disease but also substantially lowers relapse risk, with studies demonstrating nearly a six-fold reduction in recurrence odds. ICU pearls you don’t want to miss: • Autonomic instability can become life-threatening • Refractory seizures and status epilepticus are common • Dyskinesias may require deep sedation • Ventilator dependence is frequent in severe anti-NMDAR disease • Always continue aggressive rehabilitation planning early Tumor search is not optional: • Ovarian teratoma in young women with anti-NMDAR encephalitis • Thymoma in LGI1/CASPR2 syndromes • Small-cell lung cancer in classic paraneoplastic syndromes When present, tumor removal is treatment and significantly affects relapse risk and neurologic recovery. Recovery is where expectations need recalibration. Improvement is often slow, nonlinear, and incomplete despite “good” functional scores. About 75–81% of anti-NMDAR patients eventually achieve substantial recovery, but progress may continue for 24–36 months. The largest gains occur in the first 6 months, yet persistent deficits in memory, language, fatigue, emotional health, and social functioning are extremely common. One of the most important recent observations: autoimmune encephalitis patients continue improving well beyond the timeline expected for infectious encephalitis. Critically ill autoimmune cases may show functional gains throughout the entire first year, reinforcing the importance of prolonged rehab and longitudinal neurologic support. Relapse prevention matters: • Relapse occurs in roughly 12–25% • Risk rises when tumors are not removed or second-line immunotherapy is omitted • Rituximab is increasingly used as relapse-prevention therapy in high-risk patients Pediatric disease brings additional nuance: • Behavioral and psychiatric presentations dominate early • Earlier immune treatment correlates with better outcomes • Cognitive recovery trajectories differ from adults and may evolve over years We close with the system moves: (1) build an encephalitis pathway that triggers simultaneous infectious + autoimmune evaluation; (2) default to early EEG, CSF, MRI, and antibody panels; (3) begin empiric immunotherapy when suspicion is high; (4) create automatic malignancy-screening pathways; (5) escalate rapidly to rituximab when first-line response is incomplete; (6) embed rehab, neuropsychology, psychiatry, and family support early; (7) follow patients longitudinally because recovery continues long after discharge. Fast recognition, early immunotherapy, aggressive escalation, and long-term rehabilitation—autoimmune encephalitis is treatable, but only if you think about it before the antibodies come back.

In this episode of Hospital Medicine Unplugged, we unpack acute interstitial nephritis (AIN)—a frequently overlooked cause of acute kidney injury (AKI) driven largely by medications, immune reactions, and systemic diseases. We start with epidemiology clinicians should recognize. AIN accounts for roughly 15–27% of kidney biopsies performed for AKI and about 2.8% of all kidney biopsies overall. Among biopsies done specifically for acute renal failure, AIN represents ~13.5% of cases. Drug-induced AIN dominates the landscape, responsible for 70–90% of biopsy-proven cases, and its incidence appears to be rising—particularly in older adults, where polypharmacy and underutilization of kidney biopsy can obscure the diagnosis. Next we break down the most common causes. • Antibiotics are the leading class, responsible for ~49% of drug-induced AIN, especially penicillins, cephalosporins, rifampin, and fluoroquinolones. • Proton pump inhibitors account for ~14%, with omeprazole the single most common culprit drug. • NSAIDs (~11%) are another major contributor. Other causes include 5-aminosalicylates, diuretics, allopurinol, anticonvulsants, and chemotherapeutic agents. Emerging causes include immune checkpoint inhibitors, reflecting the expanding use of immunotherapy in oncology. We then explore the immunologic pathophysiology. AIN is primarily driven by T-cell–mediated hypersensitivity reactions (Type IV) targeting tubular antigens or drug-related antigens processed by tubular epithelial cells. However, IgE-mediated mast cell activation (Type I hypersensitivity) may also contribute in some cases. The resulting interstitial inflammation and edema can rapidly progress to fibrosis, making early recognition and treatment critical for renal recovery. Histologically, AIN is characterized by interstitial inflammatory infiltrates composed mainly of lymphocytes, macrophages, plasma cells, and sometimes eosinophils, along with tubulitis, interstitial edema, and tubular injury. Glomeruli are typically normal, while interstitial fibrosis and tubular atrophy signal chronicity and worse prognosis. Variants include granulomatous AIN and rare entities like IgM-positive plasma cell tubulointerstitial nephritis. Clinically, the classic triad of fever, rash, and eosinophilia is now uncommon—present in fewer than 10–15% of patients. Instead, most patients present with nonspecific symptoms such as malaise, nausea, or asymptomatic AKI. Non-oliguric AKI is typical, often accompanied by mild proteinuria and tubular dysfunction. Diagnosis relies on clinical suspicion, medication review, and supportive laboratory findings. Urinalysis may show sterile pyuria and white blood cell casts, which are more specific for AIN. Eosinophiluria, historically emphasized, is neither sensitive nor specific. Ultimately, kidney biopsy remains the gold standard when the diagnosis is uncertain. We also review emerging biomarkers that may transform diagnosis. Urinary CXCL9, an interferon-γ–induced chemokine involved in lymphocyte recruitment, has shown excellent diagnostic performance with AUC values up to ~0.94 for AIN detection. Additional candidate biomarkers include urinary TNF-α, IL-9, kidney injury molecule-1 (KIM-1), and soluble C5b-9, reflecting tubular injury and immune activation. Management begins with immediate withdrawal of the offending drug. If kidney function does not improve within 5–7 days, corticosteroid therapy is often initiated, typically prednisone ~40–60 mg daily (~0.8 mg/kg). Evidence suggests that early steroid therapy—within the first 1–2 weeks—improves renal recovery, while prolonged treatment beyond several weeks offers little additional benefit. Finally, we discuss prognosis. About 76% of patients achieve some degree of kidney recovery within six months, with complete recovery in roughly half of steroid-treated cases. However, chronic kidney disease remains common, and long-term studies suggest up to 39% of patients may eventually develop end-stage kidney disease. Poor outcomes are associated with delayed diagnosis, prolonged drug exposure, interstitial fibrosis on biopsy, dialysis requirement, and older age. The key takeaway: acute interstitial nephritis is a common, often medication-related cause of AKI that requires high clinical suspicion, prompt withdrawal of offending drugs, and early consideration of corticosteroids to prevent irreversible kidney damage.

In this episode of Hospital Medicine Unplugged, we break down celiac disease—from epidemiology and modern diagnostic strategies to life-threatening complications and emerging therapies beyond the gluten-free diet. We start with epidemiology clinicians should know. The global prevalence of celiac disease is ~1.4% based on serology and ~0.7% with biopsy confirmation. Incidence rates are ~17 per 100,000 person-years in women and ~8 per 100,000 in men, with a female-to-male ratio of ~1.8. Importantly, about 70% of cases remain undiagnosed, the so-called “celiac iceberg.” Over recent decades, incidence has increased substantially, rising from 20 per 100,000 in many regions today. Next we unpack genetic susceptibility and immune pathogenesis. Nearly all patients carry HLA-DQ2 or HLA-DQ8, but these genes alone are insufficient—~40% of the population carries them, yet only 1–3% develop disease, highlighting the role of environmental triggers and additional genetic factors. Gluten exposure leads to immune activation against deamidated gliadin peptides, resulting in small-intestinal inflammation, villous atrophy, and malabsorption. We then highlight how the clinical presentation has shifted. The classic picture of malabsorption with diarrhea and weight loss is now less common in adults. Instead, non-classical presentations predominate, including iron-deficiency anemia, osteoporosis, abnormal liver enzymes, infertility, and nonspecific GI symptoms. Diarrhea still occurs in ~40–50% of patients, but many adults present with extraintestinal manifestations or even asymptomatic disease. We also review celiac crisis, a rare but life-threatening presentation requiring hospitalization. Patients develop severe diarrhea, dehydration, electrolyte disturbances, metabolic acidosis, and profound malnutrition. Management requires intravenous fluids, electrolyte replacement, aggressive nutritional support, and sometimes corticosteroids, alongside initiation of a strict gluten-free diet, which leads to improvement in the vast majority of patients. Diagnosis begins with serologic testing. IgA tissue transglutaminase (tTG-IgA) is the preferred initial screening test, with ~93–95% sensitivity and ~95–98% specificity, and total IgA should be measured simultaneously to detect IgA deficiency. Endomysial antibody testing has near-100% specificity and can confirm the diagnosis. In adults, upper endoscopy with small-bowel biopsy remains the diagnostic standard, demonstrating intraepithelial lymphocytosis, crypt hyperplasia, and villous atrophy. We then discuss major complications clinicians must recognize. These include osteoporosis, infertility, neurologic complications, hyposplenism, and small-bowel adenocarcinoma. One of the most serious is enteropathy-associated T-cell lymphoma (EATL)—a rare but aggressive malignancy with very poor survival, often arising from type 2 refractory celiac disease. Refractory celiac disease (RCD) occurs when symptoms and villous atrophy persist despite ≥12 months of strict gluten-free diet. • Type 1 RCD behaves similarly to active celiac disease and responds to immunosuppressive therapy with excellent survival. • Type 2 RCD represents a pre-lymphoma state with clonal abnormal lymphocytes, and 30–50% progress to EATL within five years. Management still centers on the gluten-free diet, which leads to symptomatic improvement in ~70% of patients within two weeks, though histologic healing can take months and may remain incomplete in many adults. Finally, we explore the future of therapy. While diet remains the cornerstone, multiple pharmacologic strategies are in development, including gluten-degrading enzymes, intestinal barrier modulators like larazotide, transglutaminase inhibitors, immune-modulating therapies targeting IL-15, microbiome-based therapies, and even gene-edited wheat with reduced immunogenic gluten. The takeaway: celiac disease is common, frequently underdiagnosed, and increasingly recognized through non-classical presentations. With improved diagnostics, recognition of severe complications like refractory disease and lymphoma, and a rapidly evolving therapeutic pipeline, management of celiac disease is entering a new era beyond diet alone.

In this episode of Hospital Medicine Unplugged, we tackle polypharmacy and deprescribing—how to recognize problematic medication overload, quantify its harms, and apply structured, patient-centered strategies to safely reduce medication burden. We begin with definitions that shape clinical practice. Polypharmacy is most commonly defined as the use of ≥5 medications, though definitions vary. Importantly, not all polypharmacy is harmful. “Appropriate polypharmacy” occurs when medications are evidence-based and optimized, while “problematic polypharmacy” arises when medications lack clear benefit or when harms outweigh benefits. Deprescribing is the systematic process of identifying and discontinuing medications whose risks exceed benefits, aligned with a patient’s goals, function, life expectancy, and preferences. Next we review how common this problem is. Polypharmacy affects 30–40% of community-dwelling older adults, 40–50% of hospitalized older adults, and up to 90% of nursing home residents. Roughly 20–50% of older adults take at least one potentially inappropriate medication (PIM). Risk rises with multimorbidity, female sex, lower socioeconomic status, and each additional chronic disease increases the odds of polypharmacy by nearly 90%. We then quantify the clinical consequences. • Adverse drug events occur in 20–30% of hospitalized older adults, and each additional medication increases adverse reaction risk by ~10%. • Polypharmacy is associated with higher mortality (HR ~1.2–1.7) and increased hospital admissions and readmissions. • It also increases fall risk (OR ~1.6) and contributes to hip fractures, frailty, cognitive impairment, and functional decline. A key driver is the prescribing cascade, where a drug causes side effects that are treated with additional medications. Classic examples include: • NSAIDs → hypertension → antihypertensives • Cholinesterase inhibitors → urinary incontinence → anticholinergics • Calcium channel blockers → edema → diuretics • Antipsychotics → parkinsonism → antiparkinsonian drugs To identify problematic medications, we review major screening tools. • 2023 AGS Beers Criteria highlights medications to avoid or use cautiously in older adults, including guidance on benzodiazepines, antipsychotics in dementia, and aspirin for primary prevention in adults ≥70. • STOPP/START version 3 includes 94 criteria for inappropriate prescriptions and 34 for underprescribing. • Additional tools include the Medication Appropriateness Index, FORTA classification, Anticholinergic Cognitive Burden scale, and Drug Burden Index. We then walk through a practical deprescribing framework. A common 5-step protocol includes: List all medications and indications Assess overall risk of drug-related harm Identify drugs eligible for discontinuation Prioritize those with highest harm and lowest benefit Implement tapering and monitor for withdrawal or recurrence Certain medications require careful tapering to prevent withdrawal syndromes, including benzodiazepines, beta-blockers, antidepressants, corticosteroids, opioids, antiepileptics, clonidine, baclofen, and proton pump inhibitors. We highlight high-yield deprescribing targets. • Proton pump inhibitors: up to 70% lack appropriate indication; associated with C. difficile infection, pneumonia, CKD, and fractures. • Benzodiazepines: linked to falls, delirium, and cognitive impairment, with tapering success rates 27–80%. • Antipsychotics: frequently used for dementia behaviors but carry 1.6–1.7× increased mortality risk. • Anticholinergic medications: high burden strongly linked to cognitive decline and mortality. • Sliding-scale insulin: increases hypoglycemia without improving glycemic control. We also discuss patient and system barriers. Interestingly, 92% of older adults say they would stop at least one medication if their doctor recommended it, though many fear symptom recurrence or believe medications are necessary. Finally, we examine solutions that work. Pharmacist-led medication reviews reduce inappropriate medications by 21–35% and lower readmissions, while clinical decision support tools in electronic health records can flag high-risk medications and prompt deprescribing conversations. The takeaway: polypharmacy is common, harmful, and often reversible. Using structured frameworks, validated screening tools, and shared decision-making, clinicians can safely deprescribe and improve medication safety—especially for older adults with multimorbidity.

In this episode of Hospital Medicine Unplugged, we break down primary hyperparathyroidism (PHPT)—from epidemiology and pathophysiology to modern imaging, surgical indications, and evolving medical therapies. We start with who gets PHPT and how often it occurs. The condition affects ~0.8–0.9% of the general population, with an incidence of 4–6 cases per 10,000 person-years. It is 2.5 times more common in women, and incidence rises sharply with age, reaching ~12 cases per 10,000 person-years in people aged 70–79. There are also racial disparities, with higher incidence reported in Black populations. Next we unpack the causes of PHPT. About 80% of cases result from a single parathyroid adenoma, 10–11% from multiple adenomas, 1 mg/dL above normal • Age 250 mg/day in women, >300 mg/day in men) • Kidney stones or nephrocalcinosis • Symptomatic disease For patients who are not surgical candidates, several medications help control complications: • Cinacalcet lowers serum calcium and PTH but does not improve bone density • Bisphosphonates (like alendronate) improve bone density but do not lower calcium • Denosumab and combination therapy with cinacalcet may help address both hypercalcemia and bone loss We also explore normocalcemic primary hyperparathyroidism, an increasingly recognized condition defined by elevated PTH with normal calcium after excluding secondary causes. It may represent an early or milder form of PHPT, often with more multiglandular disease and slightly lower surgical cure rates. Finally, we highlight critical diagnostic pitfalls and emerging research. Distinguishing PHPT from familial hypocalciuric hypercalcemia (FHH) is essential—FHH shows lifelong mild hypercalcemia and a calcium-to-creatinine clearance ratio 0.01 and does not require surgery. Meanwhile, advanced imaging, genetic testing in younger patients, and combination pharmacotherapy are shaping the future of PHPT care. The bottom line: primary hyperparathyroidism is common, increasingly detected incidentally, and highly treatable—especially when clinicians recognize surgical indications, use modern imaging strategies, and tailor therapy to complications and patient risk.

In this episode of Hospital Medicine Unplugged, we break down ANCA-associated vasculitis (AAV)—granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA)—focusing on modern epidemiology, complement-driven pathophysiology, ANCA serotypes, and the rapidly evolving treatment landscape. We start with epidemiology clinicians should recognize. The global incidence of AAV is ~17 per million person-years, with a prevalence near 198 per million. In the United States, incidence is roughly 3.3 per 100,000, with a prevalence of ~42 per 100,000. Subtype incidence varies: GPA (~9–15/million), MPA (~6/million), and EGPA (~2/million). The mean age at diagnosis is about 61, and rates have increased over the past decades due to greater recognition and widespread ANCA testing. Next we unpack the pathophysiology that changed therapy. Complement activation—particularly the alternative pathway—plays a central role. C5a drives neutrophil activation and recruitment, creating an inflammatory amplification loop. Low C3 levels correlate with more aggressive disease and worse renal outcomes. This mechanistic insight led to avacopan, an oral C5a receptor antagonist that provides a glucocorticoid-sparing approach to treatment. We then highlight the importance of ANCA serotype classification. Patients are increasingly categorized by PR3-ANCA vs MPO-ANCA, not just clinical phenotype. • PR3-ANCA disease is more often GPA, with ENT involvement, pulmonary nodules, and higher relapse risk. • MPO-ANCA disease more often presents as MPA, with renal-limited disease, interstitial lung disease, and higher mortality. We also review EGPA as a distinct entity. Only ~40% of patients are ANCA-positive. Two clinical subsets exist: • ANCA-positive EGPA → vasculitic manifestations such as glomerulonephritis and neuropathy • ANCA-negative EGPA → eosinophilic disease with pulmonary infiltrates and cardiomyopathy Asthma is a defining feature, and cardiac involvement is a major driver of mortality. Diagnosis relies on modern ANCA testing and organ evaluation. PR3- and MPO-specific immunoassays are now the preferred screening tests, with ~90–95% sensitivity for active GPA/MPA and >95% specificity. Renal disease occurs in 70–80% of GPA/MPA, typically as pauci-immune necrotizing crescentic glomerulonephritis, while pulmonary disease ranges from nodules and cavitation (PR3) to interstitial lung disease (MPO) and diffuse alveolar hemorrhage. Management has evolved dramatically. First-line induction therapy combines glucocorticoids with rituximab or cyclophosphamide, with rituximab preferred for most patients—especially PR3-ANCA or relapsing disease. Reduced-dose steroid regimens are now recommended after trials like PEXIVAS, which showed lower infection risk without worse renal outcomes. We also cover key modern therapies. • Avacopan, a C5a receptor antagonist, improves sustained remission and kidney recovery while reducing steroid exposure. • Plasma exchange remains controversial after the PEXIVAS trial, but may still be considered in severe kidney failure, dialysis-dependent disease, or diffuse alveolar hemorrhage. For maintenance therapy, rituximab is now the preferred agent, outperforming azathioprine in major trials such as MAINRITSAN and RITAZAREM. Maintenance typically continues 2–4 years, especially in PR3-ANCA patients with high relapse risk. We finish with EGPA-specific treatment advances. IL-5 pathway inhibitors have transformed care, including mepolizumab and the newer benralizumab, which improve remission rates and allow significant glucocorticoid reduction. The bottom line: AAV management has shifted toward precision medicine—ANCA serotype classification, complement-targeted therapy, steroid-sparing strategies, and biologic maintenance treatments—dramatically improving survival and long-term outcomes.

In this episode of Hospital Medicine Unplugged, we sprint through fat-soluble vitamins—A, D, E, and K—focusing on how they’re absorbed, why deficiencies happen, and the clinical syndromes hospitalists must recognize early. From intestinal transporters to neurologic deficits and neonatal bleeding, we connect physiology to bedside decision-making. We start with absorption mechanics, which are more complex than simple passive diffusion. Modern research shows specific intestinal transporters—SR-BI, CD36, NPC1L1, and ABCA1—facilitate uptake of vitamins D, E, and K. Interestingly, vitamin A appears to lack a dedicated membrane transporter for dietary absorption. Absorption is also competitive: vitamins D, E, and K compete with one another, while vitamin A can suppress absorption of other fat-soluble vitamins without being affected itself. This interaction becomes clinically relevant in patients taking high-dose supplements. Next we tackle vitamin A—vision, epithelial integrity, and immune defense. Deficiency follows a classic progression: • Night blindness (earliest symptom) • Xerophthalmia • Bitot spots • Irreversible corneal damage and blindness Vitamin A also regulates epithelial differentiation and T-cell immune function, so deficiency increases susceptibility to infection. Even in high-income settings, restrictive diets or selective eating can lead to severe deficiency and permanent ocular injury. Toxicity is equally important. Chronic hypervitaminosis A causes: • Elevated intracranial pressure (headache, vomiting, papilledema, bulging fontanelle in infants) • Hepatotoxicity • Bone abnormalities from vitamin D receptor antagonism • Teratogenic effects Sustained doses around 50,000 IU daily for >18 months can produce chronic toxicity. We then shift to vitamin D—arguably the most clinically debated fat-soluble vitamin. Vitamin D metabolism follows a three-step pathway: UVB exposure converts 7-dehydrocholesterol in skin to vitamin D3 Hepatic conversion to 25-hydroxyvitamin D (calcidiol) Renal activation to calcitriol (1,25-dihydroxyvitamin D) This active hormone regulates calcium and phosphate homeostasis through tight feedback with parathyroid hormone. Deficiency is widespread—over one billion people globally. Classic consequences include rickets in children and osteomalacia or osteoporosis in adults, but deficiency also contributes to proximal muscle weakness, increasing fall and fracture risk. Vitamin D receptors are expressed throughout the body, and observational data link deficiency with cardiovascular disease, autoimmune disease, diabetes, multiple sclerosis, and cancer, although randomized trials show mixed results for extraskeletal benefits. A key clinical debate remains optimal levels. Many experts advocate serum 25-hydroxyvitamin D concentrations above 40–50 ng/mL, often requiring supplementation beyond traditional recommendations. Next up: vitamin E—the neurologic protector. Deficiency primarily manifests with neurologic disease, including: • Peripheral neuropathy • Cerebellar and sensory ataxia • Posterior column dysfunction • Hyporeflexia • Oculomotor abnormalities such as impaired upward gaze Severe cases can progress to blindness and dementia. In cholestatic patients, interpretation requires nuance. Vitamin E levels may appear falsely normal due to hyperlipidemia, so clinicians should measure the vitamin E–to–total lipid ratio instead. Another diagnostic clue is red blood cell acanthocytosis on blood smear. Toxicity is uncommon but high-dose vitamin E increases bleeding risk, particularly in patients taking anticoagulants. We close with vitamin K—the coagulation vitamin with expanding roles in vascular biology. Vitamin K enables γ-carboxylation of clotting factors II, VII, IX, and X and anticoagulant proteins C and S. Deficiency produces functional clotting factor impairment and bleeding once levels fall below ~30 U/dL. In neonates, vitamin K deficiency bleeding (VKDB) occurs in three forms: • Early (50% presenting with intracranial hemorrhage Routine intramuscular vitamin K prophylaxis at birth prevents nearly all cases of late VKDB. Beyond coagulation, vitamin K activates matrix Gla protein, a powerful inhibitor of vascular calcification, and osteocalcin, which supports bone metabolism. We also spotlight high-risk populations for fat-soluble vitamin deficiency, including patients with: • Cholestatic liver disease • Chronic pancreatitis and pancreatic insufficiency • Inflammatory bowel disease or celiac disease • Cystic fibrosis • Bariatric surgery • Genetic lipid disorders such as abetalipoproteinemia or α-TTP deficiency Certain medications impair absorption as well—orlistat, cholestyramine, and long-term antibiotics. Finally, we review laboratory assessment strategies that actually work. • Vitamin A: serum retinol 1–3 μmol/L normal • Vitamin D: 25-hydroxyvitamin D is the standard marker • Vitamin E: use vitamin E–to–lipid ratio in cholestasis • Vitamin K: measure phylloquinone or PIVKA-II (undercarboxylated prothrombin)—because PT/aPTT are insensitive for early deficiency Bottom line: fat-soluble vitamins depend on lipid absorption, specialized transporters, and intact hepatobiliary and pancreatic function. Recognizing malabsorption states, neurologic or ocular clues, and appropriate biomarkers is essential to diagnosing deficiency early—before irreversible complications like blindness, neuropathy, fractures, or intracranial hemorrhage occur.

In this episode of Hospital Medicine Unplugged, we sprint through thalassemia—an inherited hemoglobinopathy defined by reduced or absent globin chain production, ineffective erythropoiesis, and chronic anemia. We break down the genetics, pathophysiology, clinical spectrum, and why this disorder remains the most common monogenic disease worldwide. We start with the big picture. About 5% of the global population carries an α-thalassemia allele and 1.5% carries a β-thalassemia allele, with roughly 1.3 million people living with disease and ~40,000 affected infants born annually. The condition clusters across malaria-endemic regions—from sub-Saharan Africa and the Mediterranean to the Middle East, South Asia, and Southeast Asia—because the carrier state provides partial protection against malaria. Migration has increasingly brought thalassemia to North America and Europe, expanding its global clinical impact. Next, we revisit normal hemoglobin physiology. Adult hemoglobin (HbA) is α₂β₂, with smaller fractions of HbA₂ (α₂δ₂) and HbF (α₂γ₂). During infancy, the body transitions from fetal hemoglobin to adult hemoglobin as γ-globin declines and β-globin production increases, regulated by transcription factors such as BCL11A and KLF1. Balanced α- and β-chain production is essential—when the balance breaks, unpaired globin chains accumulate, precipitate, and damage developing red cells, driving ineffective erythropoiesis. We then dive into the genetic architecture. α-globin genes (HBA1, HBA2) sit on chromosome 16 with four total copies, while the β-globin gene (HBB) lies on chromosome 11 with two total copies. • α-thalassemia is usually caused by gene deletions affecting HBA1 or HBA2. • β-thalassemia typically results from point mutations affecting transcription, RNA splicing, or translation. Mutations are classified as: • β⁰ mutations: no β-globin production • β⁺ mutations: reduced β-globin synthesis Severity depends on genotype, but genetic modifiers matter—coinherited α-thalassemia, increased HbF production, or α-globin gene duplications can significantly alter disease expression. Next, we map the clinical classification. Alpha thalassemia spectrum: • Silent carrier: one gene affected, usually asymptomatic • α-thalassemia trait: two genes affected, mild microcytic anemia • Hemoglobin H disease: three genes affected → moderate-severe hemolytic anemia with β₄ tetramers • Hb Bart’s hydrops fetalis: four genes deleted → incompatible with life Beta thalassemia spectrum: • β-thalassemia trait: mild microcytic anemia with elevated HbA₂ (>3.5%) • β-thalassemia intermedia: moderate anemia with variable transfusion needs • β-thalassemia major (Cooley anemia): severe disease presenting in infancy requiring lifelong transfusions Compound disorders add complexity, including HbE-β thalassemia and sickle-β thalassemia, where severity depends on the interacting mutations. Then we unpack the pathophysiology driving complications. Excess unpaired globin chains cause oxidative damage and premature death of erythroid precursors, leading to: • Ineffective erythropoiesis with massive marrow expansion • Hemolysis from fragile red cells • Extramedullary hematopoiesis in liver and spleen Chronic erythropoietin stimulation leads to skeletal deformities—frontal bossing, maxillary hypertrophy, and long-bone abnormalities. Iron overload develops through two major pathways: • Transfusion iron loading (each unit adds ~200–250 mg of iron) • Increased intestinal absorption from suppressed hepcidin due to ineffective erythropoiesis The downstream damage is systemic: cardiomyopathy, arrhythmias, liver fibrosis and cirrhosis, endocrine failure (growth delay, diabetes, hypothyroidism, hypoparathyroidism), osteoporosis, and thrombosis risk. We close with the clinical spectrum. • Trait: usually asymptomatic with incidental microcytosis • Intermedia: moderate anemia (Hb ~7–10 g/dL), skeletal changes, gallstones, pulmonary hypertension, extramedullary masses • Major: early infancy presentation with severe anemia, failure to thrive, hepatosplenomegaly, and the classic “chipmunk facies” from marrow expansion Bottom line: thalassemia is a disorder of globin chain imbalance leading to ineffective erythropoiesis, hemolysis, marrow expansion, and iron overload. Understanding the genetics, modifiers, and pathophysiology is essential to predicting severity, guiding transfusion strategies, and preventing the devastating end-organ complications of chronic iron toxicity.

In this episode of Hospital Medicine Unplugged, we sprint through ankylosing spondylitis and axial spondyloarthritis—recognize inflammatory back pain early, understand the disease spectrum from non-radiographic to radiographic disease, and treat aggressively to prevent structural damage and disability. We begin with the modern concept of axial spondyloarthritis (axSpA), which represents a disease spectrum rather than a single condition. At one end is non-radiographic axial spondyloarthritis (nr-axSpA)—patients with typical symptoms but without definitive radiographic sacroiliitis. At the other end is radiographic axial spondyloarthritis (r-axSpA), historically known as ankylosing spondylitis, where structural changes in the sacroiliac joints are visible on X-ray. Globally, axial spondyloarthritis affects roughly 0.3% to 1.4% of the population, with about 1% prevalence in the United States. Disease onset typically occurs early in life—more than 80% of patients develop symptoms before age 30. Radiographic disease is more common in men, while non-radiographic disease occurs equally in men and women. A major challenge in this condition is diagnostic delay, which averages nearly seven years from symptom onset. This delay contributes to progressive inflammation, structural damage, and functional impairment before effective therapy is started. The pathogenesis of axial spondyloarthritis involves a combination of genetic susceptibility, immune dysregulation, and environmental triggers. The strongest genetic risk factor is HLA-B27, present in 80–90% of patients with ankylosing spondylitis. Several mechanisms have been proposed to explain how HLA-B27 contributes to disease: • Presentation of arthritogenic peptides to CD8+ T cells • Formation of HLA-B27 dimers, which activate innate immune receptors • Misfolding of HLA-B27 proteins, triggering an unfolded protein response and increased cytokine signaling At the center of the inflammatory cascade lies the IL-23 / IL-17 axis, which drives activation of Th17 cells and production of pro-inflammatory cytokines including IL-17 and TNF-α. Mechanical stress at the entheses—the sites where ligaments and tendons attach to bone—triggers inflammation, making enthesitis the hallmark pathological process. Chronic inflammation eventually stimulates pathologic new bone formation, producing syndesmophytes and spinal ankylosis. Clinically, the hallmark symptom is inflammatory back pain, present in more than 80% of patients. Key features include: • Onset before age 45 years • Gradual onset • Morning stiffness lasting more than 30 minutes • Improvement with exercise • No improvement with rest Extra-articular manifestations are common and often provide diagnostic clues. The most frequent is acute anterior uveitis, occurring in 25–30% of patients. Episodes typically present with sudden eye pain, redness, photophobia, and blurred vision. Other associated conditions include: • Inflammatory bowel disease (5–10%) • Psoriasis (about 10%) • Cardiovascular involvement, including aortic regurgitation and conduction abnormalities • Pulmonary restriction due to chest wall rigidity Because early disease may not show radiographic damage, classification relies on modern criteria. The Modified New York Criteria require definite radiographic sacroiliitis and therefore identify only advanced disease. In contrast, the ASAS classification criteria for axial spondyloarthritis allow earlier diagnosis. These criteria apply to patients with chronic back pain lasting ≥3 months with onset before age 45 and include two diagnostic pathways: • Imaging arm: sacroiliitis on MRI or radiograph plus ≥1 SpA feature • Clinical arm: HLA-B27 positivity plus ≥2 SpA features These criteria have approximately 83% sensitivity and 84% specificity, enabling detection of earlier disease stages. Monitoring disease activity is critical to guide treatment decisions. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred measure because it incorporates both patient-reported symptoms and inflammatory markers such as CRP. ASDAS categories include: • Inactive disease: 3.5 Management begins with non-pharmacologic therapy, which remains foundational for all patients. This includes structured exercise programs, physical therapy, posture training, and smoking cessation, as smoking is associated with worse radiographic progression and poorer treatment response. First-line pharmacologic therapy is NSAIDs, which reduce pain and inflammation. Continuous therapy may be more effective than intermittent use, although fewer than one quarter of patients achieve complete symptom control with NSAIDs alone. For patients with persistent disease activity, biologic therapy is the next step. TNF inhibitors were the first biologics proven effective, producing ASAS20 response rates of roughly 60% and reducing radiographic progression. More recently, IL-17 inhibitors such as secukinumab and ixekizumab have shown comparable efficacy. A newer agent, bimekizumab, blocks both IL-17A and IL-17F, offering promising results. JAK inhibitors, including upadacitinib and tofacitinib, provide an oral treatment option and demonstrate response rates exceeding 50%, though regulatory agencies caution about risks including cardiovascular events and infections. Despite the strong genetic association with IL-23, IL-23 inhibitors have not demonstrated clinical benefit in axial spondyloarthritis, highlighting the complexity of immune signaling pathways. Long-term outcomes vary widely. The strongest predictor of future structural damage is existing syndesmophytes at baseline. Other poor prognostic factors include male sex, smoking, early hip involvement, and persistent systemic inflammation. Complications can also arise from the structural rigidity of the spine. Osteoporosis and vertebral fractures occur in up to 10% of patients, meaning new spinal pain—even after minor trauma—should prompt evaluation for fracture. We close with the key clinical takeaways: • Axial spondyloarthritis is a spectrum ranging from non-radiographic disease to classic ankylosing spondylitis • Inflammatory back pain beginning before age 45 is the key clinical clue • HLA-B27 and the IL-23/IL-17 inflammatory pathway play central roles in pathogenesis • MRI allows earlier diagnosis before radiographic damage appears • Biologic therapies targeting TNF and IL-17 dramatically improve disease control Early recognition and treatment are critical—because once structural ankylosis develops, damage is irreversible.

In this episode of Hospital Medicine Unplugged, we sprint through prosthetic heart valves—how to choose between mechanical and bioprosthetic valves, manage anticoagulation safely, recognize complications, and navigate the expanding role of transcatheter valve replacement. We begin with the two major categories of prosthetic valves: mechanical valves and bioprosthetic (tissue) valves. Mechanical valves are constructed from durable materials such as pyrolytic carbon and are designed to last decades, but their thrombogenic surface requires lifelong anticoagulation with a vitamin K antagonist. Anticoagulation targets depend on valve position and risk factors. • Mechanical aortic valve: target INR 2.5 • Mechanical mitral valve or high-risk aortic valve: target INR 3.0 In most patients, low-dose aspirin (75–100 mg daily) is added to vitamin K antagonist therapy to further reduce thromboembolic risk. Bioprosthetic valves, in contrast, are made from porcine valves or bovine pericardium. These valves are less thrombogenic, which allows for short-term anticoagulation (typically 3–6 months) after implantation followed by lifelong antiplatelet therapy with aspirin. The trade-off is durability—structural valve degeneration (SVD) eventually occurs due to calcification, fibrosis, or leaflet tearing. Choosing between valve types requires balancing durability versus anticoagulation risk. Mechanical valves generally offer better long-term durability, while bioprosthetic valves avoid lifelong anticoagulation but may require future reoperation. Age is one of the most important factors in valve selection. Evidence from large observational studies demonstrates that mechanical valves provide survival advantages in younger patients, particularly: • Aortic valve replacement: survival benefit up to about age 55 • Mitral valve replacement: survival benefit up to about age 70 Current ACC/AHA guidelines generally recommend: • Mechanical valves: younger patients (50 years for aortic position, 65 years for mitral) • Bioprosthetic valves: older patients or those with contraindications to long-term anticoagulation The treatment landscape has changed dramatically with the development of transcatheter aortic valve replacement (TAVR). Initially reserved for patients with prohibitive surgical risk, TAVR is now widely used across risk groups. Landmark trials such as PARTNER 3 demonstrated that in low-risk patients with severe aortic stenosis, TAVR produced outcomes comparable to surgical valve replacement at five years. TAVR offers advantages including lower rates of atrial fibrillation and bleeding, though it carries higher risks of paravalvular regurgitation and pacemaker implantation. Guidelines now recommend: • TAVR as a Class I option for patients who are inoperable or high surgical risk • Either TAVR or surgical replacement for patients aged 65–80 years, depending on anatomy and patient factors Anticoagulation management remains one of the most critical aspects of prosthetic valve care. Direct oral anticoagulants (DOACs are contraindicated in mechanical valves). The RE-ALIGN trial showed increased thromboembolic and bleeding complications with dabigatran compared with warfarin, leading to early termination of the study. More recently, the PROACT Xa trial evaluating apixaban in patients with On-X mechanical valves also demonstrated excess thromboembolic events. For bioprosthetic valves, however, DOACs may be used in patients who develop atrial fibrillation, although long-term data remain limited. Despite technological advances, prosthetic valves carry important complications. One of the most serious is prosthetic valve endocarditis (PVE), which is associated with high mortality. Management requires prolonged intravenous antibiotics, typically for at least six weeks, and surgery may be required for heart failure, uncontrolled infection, or large vegetations. Another major complication is prosthetic valve thrombosis, particularly with mechanical valves. Management depends on clinical severity and thrombus size. Options include urgent surgery or low-dose, slow-infusion fibrinolysis, with modern thrombolytic protocols achieving over 90% success rates and low complication rates. A subtler but clinically important issue is prosthesis–patient mismatch (PPM). This occurs when the effective orifice area of the prosthetic valve is too small relative to the patient’s body surface area, creating persistent obstruction despite valve replacement. Severe PPM is defined as indexed effective orifice area 0.65 cm²/m² and is associated with higher mortality, reduced left ventricular mass regression, and worse heart failure outcomes. Certain populations require special consideration. Pregnancy with mechanical valves carries substantial maternal and fetal risk due to the competing challenges of anticoagulation and thrombosis prevention. Warfarin provides the most reliable valve protection but carries risk of embryopathy at higher doses. For women planning pregnancy, bioprosthetic valves are often preferred, even though they may require earlier replacement. Finally, structural valve degeneration is the major limitation of bioprosthetic valves. The process occurs gradually and progresses through stages—from early structural changes without hemodynamic impact to severe valve dysfunction requiring reintervention. Risk factors for accelerated degeneration include younger age, renal disease, hypertension, hyperparathyroidism, and prosthesis–patient mismatch. Because degeneration can occur silently, lifelong surveillance with periodic echocardiography is essential for all patients with prosthetic valves. We close with the key clinical takeaways: • Mechanical valves offer durability but require lifelong warfarin therapy • Bioprosthetic valves avoid chronic anticoagulation but eventually degenerate • DOACs are contraindicated in mechanical valves • TAVR has expanded treatment options across all surgical risk groups • Complications include thrombosis, prosthetic valve endocarditis, structural degeneration, and prosthesis–patient mismatch Prosthetic valve management is a lifelong process—successful outcomes depend not only on the procedure itself but on careful anticoagulation, surveillance, and early recognition of complications.

In this episode of Hospital Medicine Unplugged, we sprint through asbestosis—understand how inhaled fibers trigger progressive pulmonary fibrosis, recognize key radiographic features, and manage patients with attention to malignancy risk and progressive fibrotic disease. We start with pathophysiology, where the story begins decades before symptoms appear. After inhalation, asbestos fibers deposit in the distal airways and alveoli. Alveolar macrophages attempt to engulf these fibers, but many fibers are too long to be fully internalized—triggering “frustrated phagocytosis.” This leads to persistent macrophage activation and release of inflammatory mediators including TNF-α, IL-1, and TGF-β. At the same time, reactive oxygen species form both from macrophage activation and from iron on the fiber surface, amplifying oxidative injury. A key early event is alveolar epithelial cell apoptosis, driven by mitochondrial injury, p53-mediated pathways, and endoplasmic reticulum stress. Loss of epithelial integrity and chronic inflammation stimulate fibroblast activation and collagen deposition, ultimately producing the progressive interstitial fibrosis that defines asbestosis. Not all asbestos fibers carry the same risk. Amphibole fibers—particularly crocidolite and amosite—are far more fibrogenic and carcinogenic than chrysotile fibers. Their needle-like shape, durability, and resistance to biological clearance allow them to persist in lung tissue for decades. Fiber dimensions matter: long fibers (>10–20 μm) and extremely thin fibers (0.25 μm) pose the highest disease risk because they reach distal lung regions and resist macrophage clearance. One of the defining features of asbestos disease is extraordinary latency. Clinical asbestosis usually develops 20–40 years after the first exposure, with peak disease occurrence around 40–45 years after exposure begins. Lung cancer tends to occur earlier, typically 30–35 years after exposure. Disease progression varies—some patients remain stable while others develop progressive fibrotic lung disease with significant annual declines in FVC, particularly those with fibrotic patterns on HRCT. Diagnosis relies on a combination of exposure history, latency, imaging, and pulmonary function testing. According to consensus guidelines, the diagnosis requires: • Documented asbestos exposure • Appropriate latency interval • Radiographic evidence of interstitial fibrosis • Restrictive lung disease with reduced DLCO While chest X-ray can detect classic small irregular opacities, high-resolution CT is far more sensitive. Key HRCT findings include: • Subpleural curvilinear lines (one of the most specific findings) • Intralobular and interlobular septal thickening • Parenchymal bands • Honeycombing in advanced disease Importantly, most patients with asbestosis also show benign pleural abnormalities, such as pleural plaques or diaphragmatic pleural thickening, which strongly support asbestos exposure. Unfortunately, no disease-modifying therapies are currently approved specifically for asbestosis. Management traditionally focuses on supportive care, including: • Smoking cessation • Vaccination against influenza and pneumococcus • Pulmonary rehabilitation • Oxygen therapy for hypoxemia However, the treatment landscape is evolving. Because asbestosis can behave like other progressive fibrosing interstitial lung diseases, antifibrotic therapies are increasingly considered for patients with progressive disease. Nintedanib, approved for progressive fibrosing ILD, may slow lung function decline in patients with progressive asbestosis. Early studies of pirfenidone suggest acceptable safety and potential benefit, though definitive evidence remains limited. Another critical dimension of asbestos exposure is malignancy risk. Asbestos causes two to six times more lung cancers than mesotheliomas, making asbestos-related lung cancer a major public health burden. The interaction with smoking is particularly dangerous: asbestos and smoking have a synergistic effect on lung cancer risk. In exposed workers, the combined effect can increase lung cancer mortality more than 30-fold. Importantly, asbestos exposure increases lung cancer risk even in nonsmokers, but smoking cessation dramatically reduces risk over time. Within 10 years of quitting, lung cancer mortality drops significantly, and after 30 years, risk approaches that of never-smokers. For malignant mesothelioma, amphibole fibers again carry the greatest risk. Crocidolite exposure has the highest potency, and mesothelioma risk continues to rise 40–50 years after initial exposure. Because treatment options for mesothelioma remain limited, prevention and early detection are essential. The most effective intervention is elimination of exposure, enforced through occupational safety regulations, air monitoring, and protective equipment. For individuals with significant asbestos exposure, low-dose CT screening can help detect early lung cancers, improving survival outcomes. Unfortunately, routine screening for mesothelioma is not currently recommended, as effective early detection strategies remain lacking. We close with the key clinical takeaways: • Asbestosis results from chronic macrophage activation and epithelial injury triggered by persistent asbestos fibers • Amphibole fibers pose the highest risk due to their durability and biopersistence • Disease latency often exceeds 20–40 years • HRCT is the most sensitive imaging modality for diagnosis • Antifibrotic therapies may benefit patients with progressive fibrotic phenotypes • Smoking cessation dramatically reduces asbestos-related lung cancer risk Asbestosis remains a preventable occupational disease, but its long latency means clinicians continue to encounter its consequences decades after exposure—making exposure history, imaging recognition, and malignancy surveillance critical in modern clinical practice.